Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD (COPD-OMA)
Sponsor: American Lung Association
A PHASE2 clinical study on Allergies and Chronic Obstructive Pulmonary Disease (COPD), this trial is actively recruiting participants. The trial is conducted by American Lung Association and has accumulated 6 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2025 — Feb 2026 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Not Yet Recruiting PHASE2
▶ Show 1 earlier version
-
Aug 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- American Lung Association
- American Lung Association Asthma Clinical Research Centers
- Genentech, Inc.
- Johns Hopkins University
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States, Baltimore, United States, Birmingham, United States, Chicago, United States, Colchester, United States, Denver, United States, Detroit, United States, Durham, United States, Houston, United States, Iowa City, United States and 9 more location s